Financing ·
Relay Therapeutics filed an 8-K on August 6, 2026, announcing the amendment to its At-the-Market (ATM) equity offering…
RLAYRelay Therapeutics, Inc.
Relay Therapeutics filed an 8-K on August 6, 2026, announcing the amendment to its At-the-Market (ATM) equity offering program with TD Securities. The amendment increases the aggregate offering size from $250 million to $462,978,049. Approximately $162,978,049 had already been sold under the original agreement as of the filing date. Concurrently, the company reported second-quarter 2026 financial results, reporting a net loss of $83.7 million ($0.41 per share) on revenue of $0.4 million. The company ended the quarter with $910.9 million in cash and investments, providing an expected operating runway into 2029. Relay Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for cancer and genetic diseases.